{
    "organizations": [],
    "uuid": "1982526480a1b2e4231c7d131de42b9f6872818e",
    "author": "Joseph Walker",
    "url": "https://www.wsj.com/articles/drugmaker-raises-u-s-price-of-muscular-dystrophy-treatment-1516295645",
    "ord_in_thread": 0,
    "title": "Drugmaker Raises U.S. Price of Muscular-Dystrophy Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "PTC Therapeutics Inc. this month increased the list price of its muscular-dystrophy treatment by about 9%, to more than $65,000 annually for a common dosage.\n\nThe price increase again puts a spotlight on Emflaza, a decades-old steroidal drug that many U.S. patients had been paying $1,200 or less annually to import from Europe before the Food and Drug Administration last year approved the drug for U.S. sale as a treatment for Duchenne muscular dystrophy. The rare genetic disease affects up to 12,000 Americans, most of whom...  ",
    "published": "2018-01-18T19:14:00.000+02:00",
    "crawled": "2018-01-18T21:38:59.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "ptc",
        "therapeutic",
        "month",
        "increased",
        "list",
        "price",
        "treatment",
        "annually",
        "common",
        "dosage",
        "price",
        "increase",
        "put",
        "spotlight",
        "emflaza",
        "steroidal",
        "drug",
        "many",
        "patient",
        "paying",
        "less",
        "annually",
        "import",
        "europe",
        "food",
        "drug",
        "administration",
        "last",
        "year",
        "approved",
        "drug",
        "sale",
        "treatment",
        "duchenne",
        "muscular",
        "dystrophy",
        "rare",
        "genetic",
        "disease",
        "affect",
        "american"
    ]
}